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1. General methods 
 
All air- and moisture-sensitive manipulations were carried out in anhydrous solvents 
and under argon. Toluene, tetrahydrofuran and acetonitrile were dried over the PureSolv 
MD purification system. Melting points were taken in open-end capillary tubes. 
Reactions were monitored by thin-layer chromatography carried out on 0.25 mm silica 
gel plates (230-400 mesh). Flash column chromatographies were performed using silica 
gel (230-400 mesh). NMR spectra were recorded on 300 or 500 MHz instrument and 
calibrated using residual non-deuterated solvent (CDCl3 or benzene-d6) as internal 
reference (=7.26 ppm, =77.2 ppm for CDCl3 and =7.16 ppm, =128.5 ppm for 
benzene-d6). HRMS spectra were recorded on a TOF mass spectrometer with 
electrospray ionization (ES) as the ionization source. The chromatograms of the racemic 
and enantiomerically enriched cycloadducts were obtained by HPLC or SFC. 
Arylcyclobutenones 2a, 2b, 2c, 2d, and 2e were prepared following the procedure 
reported in the literature.1 α-Iminoesters were prepared by condensation of methyl 
glycinate hydrochloride and the corresponding aldehydes.2 Due to their lability, all α-
iminoesters once isolated were immediately used in the 1,3-dipolar cycloaddition 
without further purification. 
 
                                                
1. Sugimoto, K.; Hayashi, R.; Nemoto, H.; Toyooka, N.; Matsyua, Y. Org. Lett., 2012, 14, 3510.  
2. a) Cabrera, S.; Arrayás, R. G.; Carretero, J. C. J. Am. Chem. Soc. 2005, 127, 16394; b) Nájera, C.; 
Sansano, J. M. Curr. Org. Chem. 2003, 7, 1105; c) Cooper, D. M.; Grigg, R.; Hargreaves, S.; Kennewell, 
P.; Redpath, J. Tetrahedron 1995, 51, 7791.  
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2. Typical procedure for the asymmetric 1,3-dipolar cycloaddition. 
(1S, 3R, 3aS, 5aR)-Methyl-3,5a-diphenyl-4-(oxo)heptahydrocyclobuta[c]pyrrole-1-
carboxylate (endo-3a). 
To a solution of [Cu(CH3CN)4]PF6 (19.3 mg, 0.052 mmol) and 
(R)-Fesulphos (28.6 mg, 0.062 mmol) in toluene (8 mL), under 
nitrogen atmosphere, at 0 °C, a solution of α-iminoester 1a (368.2 
mg, 2.08 mmol) in toluene (6.24 mL), KOtBu (1M in THF) (208 µl, 0.208 mmol) and a 
solution of 3-phenylcyclobutenone 2a (150 mg, 1.04 mmol) in toluene (6 mL) were 
successively added. After 24h at 0 °C, the mixture was diluted with 50 mL of CH2Cl2 
and filtered through a plug of celite®. The solvent was evaporated under reduced 
pressure and the residue was purified by silica gel flash chromatography 
(cyclohexane/EtOAc 6:1) to afford the cycloadduct endo-3a (282.5 mg, 84%, colorless 
oil). 
[α]D
20 : +35.8 (c=0.22, CHCl3), 90% ee. 
SFC: The enantiomeric excess was determined by SFC using a Chiralpak-ID-3 column 
[CO2/MeOH from 95:5 to 60:40 in 8 min, 2.0 mL/min (λ = 230.4 nm)]: tR= 2.584 min 
(1R, 3S, 3aR, 5aS)-3a and 3.072 min (1S, 3R, 3aS, 5aR)-3a. 
1
H-NMR (300 MHz, CDCl3): δ 7.46 – 7.30 (m, 10H), 4.73 (d, J = 7.3 Hz, 1H), 4.21 (s, 
1H), 3.92 (ddd, J = 7.2, 3.9, 2.1 Hz, 1H), 3.73 (s, 3H), 3.53 (dd, J = 18.4, 2.1 Hz, 1H), 
3.43 (dd, J = 18.4, 3.9 Hz, 1H). 
13
C-NMR (75 MHz, CDCl3): δ 205.1, 170.7, 142.2, 136.6, 128.7, 128.5, 128.2, 127.4, 
127.3, 127.2, 71.3, 65.0, 56.9, 53.6, 52.2, 47.6. 
HRMS (ESI+): calcd for C20H20NO3, 322.1443; found, 322.1425 ([M+H], 100). 
 
(1S, 3R, 3aS, 5aR)-Methyl-5a-phenyl-3-(4-methoxyphenyl)-4-(oxo)heptahydrocy-
clobuta[c]-pyrrole-1-carboxylate (endo-3b). 
Following the typical procedure, the reaction of 3-
phenylcyclobutenone 2a (14.4mg, 0.1 mmol) and 1b (41.4 
mg, 0.2 mmol) afforded, after purification by silica gel flash 
chromatography (cyclohexane/EtOAc 6:1), the cycloadduct endo-3b (26.9 mg, 77%, 
yellow oil). 
[α]D
20 : +44.8 (c=0.22, CHCl3), 98% ee. 
HPLC: The enantiomeric excess was determined by HPLC using a Daicel Chiralpak IB 
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column, n-hexane/isopropanol 95:5, flow rate 0.7 mL/min (λ = 230.16 nm): tR= 81.2 
min (1R, 3S, 3aR, 5aS)-3b and 103.1 min (1S, 3R, 3aS, 5aR)-3b. 
1
H-NMR (300 MHz, CDCl3): δ 7.46-7.28 (m, 7H), 6.89 (d, J = 8.5 Hz, 2H), 4.69 (d, J = 
7.2 Hz, 1H), 4.20 (s, 1H), 3.91-3.83 (m, 1H), 3.81 (s, 3H), 3.73 (s, 3H), 3.57-3.48 (m, 
1H), 3.42 (dd, J = 18.4, 3.8 Hz, 1H). 
13
C-NMR (75 MHz, CDCl3): δ 206.7, 170.9, 159.4, 142.4, 129.0, 128.7, 128.4, 127.5, 
127.2, 113.9, 71.4, 64.7, 55.4, 53.6, 52.1, 47.7. 
HRMS (ESI+): calcd for C21H22NO4, 352.1549; found, 352.1536 ([M+H], 100). 
 
(1S, 3R, 3aS, 5aR)-Methyl-5a-phenyl-3-(4-chlorophenyl)-4(oxo)heptahydrocyclo-
buta[c]pyrrole-1-carboxylate (endo-3c). 
Following the typical procedure, the reaction of 3-
phenylcyclobutenone 2a (14.4mg, 0.1 mmol) and 1c (42.3 mg, 
0.2 mmol) afforded, after purification by silica gel flash 
chromatography (cyclohexane/EtOAc 6:1), the cycloadduct endo-3c (26.9 mg, 84%, 
white solid).  
M.p.: 134-136 °C. 
[α]D
20 : +26.2 (c=0.22, CHCl3), 81% ee. 
HPLC: The enantiomeric excess was determined by HPLC using a Daicel Chiralpak IB 
column, n-hexane/isopropanol 95:5, flow rate 0.7 mL/min (λ = 230.16 nm): tR= 53.0 
min (1R, 3S, 3aR, 5aS)-3c and 61.1 min (1S, 3R, 3aS, 5aR)-3c. 
1
H-NMR (300 MHz, CDCl3): δ 7.44 – 7.30 (m, 9H), 4.70 (d, J = 7.1 Hz, 1H), 4.20 (s, 
1H), 3.90 – 3.85 (m, 1H), 3.73 (s, 3H), 3.56-3.48 (m, 1H), 3.48-3.39 (m, 1H), 2.75 (bs, 
1H). 
13
C-NMR (75 MHz, CDCl3): δ 205.7, 170.9, 159.4, 142.3, 128.9, 128.7, 128.3, 127.4, 
127.1, 113.8, 71.3, 64.7, 55.3, 53.5, 52.1, 47.6. 
HRMS (ESI+): calcd for C20H19NO3Cl, 356.1053; found, 356.1052 ([M+H], 100). 
 
(1S, 3R, 3aS, 5aR)-Methyl-5a-phenyl-3-(4-methoxycarbonyl)phenyl-4(oxo)hepta-
hydrocyclobuta[c]pyrrole-1-carboxylate (endo-3d). 
Following the typical procedure, the reaction of 3-
phenylcyclobutenone 2a (14.4mg, 0.1 mmol) and 1d 
(47.0 mg, 0.2 mmol) afforded, after purification by silica 
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gel flash chromatography (cyclohexane/EtOAc 6:1), the cycloadduct endo-3d (27.7 mg, 
73%, yellow solid). 
M.p.: 142-144 °C. 
[α]D
20 : +19.3 (c=0.22, CHCl3), 85% ee. 
HPLC: The enantiomeric excess was determined by HPLC using a Daicel Chiralpak IB 
column, n-hexane/isopropanol 95:5, flow rate 0.7 mL/min (λ = 230.16 nm): tR= 32.8 
min (1R, 3S, 3aR, 5aS)-3d and 35.6 min (1S, 3R, 3aS, 5aR)-3d. 
1
H-NMR (300 MHz, CDCl3): δ 7.91 (d, J = 8.9 Hz, 2H), 7.38 (d, J = 8.2 Hz, 2H), 7.30 
– 7.26 (m, 4H), 7.13 (s, 1H), 4.65 (d, J = 7.0 Hz, 1H), 4.09 (s, 1H), 3.85-3.80 (m, 1H), 
3.79 (s, 3H), 3.61 (s, 3H), 3.45-3.36 (m, 1H), 3.32 (dd, J = 18.6, 3.3 Hz, 1H), 2.66 (bs, 
1H). 13C-NMR (75 MHz, CDCl3): δ 206.1, 170.7, 166.9, 142.4, 142.2, 129.8, 129.7, 
128.7, 127.4, 127.3, 127.1, 76.0, 71.3, 64.5, 53.8, 52.18, 52.16, 47.4. 
HRMS (ESI+): calcd for C22H22NO5, 380.1498; found, 380.1498 ([M+H], 100). 
 
(1S, 3R, 3aS, 5aR)-Methyl-5a-phenyl-3-(3-methoxyphenyl)-4(oxo)heptahydrocyclo-
buta[c]-pyrrole-1-carboxylate (endo-3e). 
Following the typical procedure, the reaction of 3-
phenylcyclobutenone 2a (14.4mg, 0.1 mmol) and 1e (41.4 
mg, 0.2 mmol) afforded, after purification by silica gel flash 
chromatography (cyclohexane/EtOAc 6:1), the cycloadduct endo-3e (27.1 mg, 72%, 
yellow oil). 
[α]D
20 : +48.6 (c=0.22, CHCl3), 85% ee. 
HPLC: The enantiomeric excess was determined by HPLC using a Daicel Chiralpak IB 
column, n-hexane/isopropanol 95:5, flow rate 0.7 mL/min (λ = 210.8 nm): tR= 142.5 
min (1S, 3R, 3aS, 5aR)-3e and 215.8 min (1R, 3S, 3aR, 5aS)-3e. 
1
H-NMR (300 MHz, CDCl3): δ 7.45-7.38 (m, 4H), 7.36-7.24 (m, 2H), 7.04-6.96 (m, 
2H), 6.88-6.81 (m, 1H), 4.70 (d, J = 7.1 Hz, 1H), 4.19 (s, 1H), 3.93 – 3.86 (m, 1H), 3.82 
(s, 3H), 3.73 (s, 3H), 3.59-3.48 (m, 1H), 3.42 (dd, J = 18.5, 3.7 Hz, 1H), 2.77 (bs, 1H). 
13
C-NMR (75 MHz, CDCl3): δ 205.3, 170.8, 159.7, 142.3, 138.7, 129.4, 128.7, 127.4, 
127.2, 119.4, 113.5, 112.8, 76.6, 71.3, 64.9, 55.3, 53.6, 52.1, 47.5. 
HRMS (ESI+): calcd for C21H22NO4, 352.1549; found, 352.1542 ([M+H], 100). 
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(1S, 3R, 3aS, 5aR)-Methyl-5a-phenyl-3-(3-methylphenyl)-4-(oxo)heptahydrocyclo-
buta[c]pyrrole-1-carboxylate (endo-3f). 
Following the typical procedure, the reaction of 3-
phenylcyclobutenone 2a (14.4mg, 0.1 mmol) and 1f (38.2 mg, 
0.2 mmol) afforded, after purification by silica gel flash 
chromatography (cyclohexane/EtOAc 6:1), the cycloadduct endo-3f (27.9 mg, 84%, 
colorless oil). 
[α]D
20 : +74.4 (c=0.22, CHCl3), 86% ee. 
SFC: The enantiomeric excess was determined by SFC using a Chiralpak ID-3 column 
[CO2/MeOH 95:5 in 60 min, flow rate 2.0 mL/min (λ = 210.4 nm)]: tR= 4.996 min (1R, 
3S, 3aR, 5aS)-3f and 8.527 min (1S, 3R, 3aS, 5aR)-3f. 
1
H-NMR (300 MHz, CDCl3): δ 7.21-7.16 (m, 1H), 7.15-7.04 (m, 7H), 7.00 –6.95 (m, 
1H), 4.55 (d, J = 7.2 Hz, 1H), 4.05 (s, 1H), 3.78-3.73 (m, 1H), 3.59 (s, 3H), 3.38 (dd, J 
= 18.5, 1.9 Hz, 1H), 3.28 (dd, J = 18.5, 3.9 Hz, 1H), 2.61 (bs, 1H), 2.22 (s, 3H). 
13
C-NMR (75 MHz, CDCl3): δ 205.4, 170.9, 142.3, 138.0, 136.9, 128.9, 128.7, 128.3, 
127.7, 127.4, 127.2, 124.2, 71.4, 65.0, 53.6, 52.1, 47.6, 29.8, 21.6. 
HRMS (ESI+): calcd for C21H22NO3, 336.1594; found, 336.1600 ([M+H], 100). 
 
(1S, 3R, 3aS, 5aR)-Methyl-5a-phenyl-3-(2-bromophenyl)-4-(oxo)heptahydrocyclo-
buta[c]-pyrrole-1-carboxylate (endo-3g). 
Following the typical procedure, the reaction of 3-
phenylcyclobutenone 2a (14.4mg, 0.1 mmol) and 1g (51.2 mg, 
0.2 mmol) afforded, after purification by silica gel flash 
chromatography (cyclohexane/EtOAc 6:1), the cycloadduct endo-3g (30.0 mg, 72%, 
white solid). 
M.p.: 150-152 °C. 
[α]D
20 : +70.2 (c=0.22, CHCl3), 92% ee. 
SFC: The enantiomeric excess was determined by SFC using a Chiralpak-ID-3 column 
[CO2/MeOH from 95:5 to 60:40 in 8 min, 2.0 mL/min (λ = 230.4 nm)]: tR= 2.411 min 
(1R, 3S, 3aR, 5aS)-3g and 2.866 min (1S, 3R, 3aS, 5aR)-3g. 
1
H-NMR (300 MHz, CDCl3): δ 7.68 (dd, J = 7.9, 1.6 Hz, 1H), 7.57 (dd, J = 7.9, 1.6 Hz, 
1H), 7.49-7.43 (m, 4H), 7.37 – 7.28 (m, 2H), 7.18 (td, J = 7.7, 1.7 Hz, 1H), 4.98 (d, J = 
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6.8 Hz, 1H), 4.21 (s, 1H), 4.18 (ddd, J = 6.8, 3.4, 1.9 Hz, 1H), 3.74 (s, 3H), 3.52 (dd, J = 
18.4, 1.9 Hz, 1H), 3.43 (dd, J = 18.4, 3.4 Hz, 1H), 2.62 (bs, 1H). 
13
C-NMR (75 MHz, CDCl3): δ 205.5 , 170.9 , 142.6 , 136.5 , 132.7 , 129.5 , 128.7 , 
128.6, 127.6 , 127.2 , 123.2 , 73.1 , 70.8 , 63.6 , 54.0, 52.1 , 46.9. 
HRMS (ESI+): calcd for C20H19NO3Br, 400.0548; found, 400.0518 ([M+H], 100). 
 
(1S, 3R, 3aS, 5aR)-Methyl-5a-phenyl-3-(1-naphthyl)-4-(oxo)heptahydrocyclo-
buta[c]pyrrole-1-carboxylate (endo-3h). 
Following the typical procedure, the reaction of 3-
phenylcyclobutenone 2a  (14.4mg, 0.1 mmol) and 1h (45.4 
mg, 0.2 mmol) afforded, after purification by silica gel flash 
chromatography (cyclohexane/EtOAc 6:1), the cycloadduct endo-3h (33.4 mg, 90%, 
white solid). 
M.p.: 108-110 °C. 
[α]D
20 : +23.4 (c=0.22, CHCl3), 97% ee. 
SFC: The enantiomeric excess was determined by SFC using a Chiralpak-ID-3 column 
[CO2/MeOH from 95:5 to 60:40 in 8 min, 2.0 mL/min (λ = 230.4 nm)]: tR= 3.597 min 
(1R, 3S, 3aR, 5aS)-3h and 4.319 (min) (1S, 3R, 3aS, 5aR)-3h. 
1
H-NMR (300 MHz, CDCl3): δ 8.01-7.81 (m, 5H), 7.58-7.35 (m, 7H), 7.45-7.34 (m, 
7H), 5.43 (d, J = 6.9 Hz, 1H), 4.34 (s, 1H), 4.20-4.14 (m, 1H), 3.77 (s, 3H), 3.57 (dd, J 
= 18.4, 2.5 Hz, 1H), 3.44 (dd, J = 18.4, 3.9 Hz, 1H). 
13
C-NMR (75 MHz, CDCl3): δ 205.1, 171.0, 142.6, 133.8, 132.7, 130.9, 129.5, 128.8, 
128.5, 127.6, 127.3, 126.4, 125.7, 125.6, 124.0, 122.2, 74.9, 70.9, 60.8, 54.0, 52.2, 47.3. 
HRMS (ESI+): calcd for C24H22NO3, 372.1600; found, 372.1609 ([M+H], 100). 
 
(1S, 3R, 3aS, 5aR)-Methyl-5a-phenyl-3-(furan-2-yl)-4-(oxo)heptahydrocyclo-
buta[c]pyrrole-1-carboxylate (endo-3i). 
Following the typical procedure, the reaction of 3-
phenylcyclobutenone 2a (14.4mg, 0.1 mmol) and 1i (33.4 mg, 0.2 
mmol) afforded, after purification by silica gel flash 
chromatography (cyclohexane/EtOAc 6:1), the cycloadduct endo-3i (24.9 mg, 80%, 
yellow oil). 
[α]D
20 : +18.1 (c=0.22, CHCl3), 88% ee. 
HPLC: The enantiomeric excess was determined by HPLC using a Daicel Chiralpak IB 
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column, n-hexane/isopropanol 95:5, flow rate 0.7 mL/min (λ = 210.8 nm): tR= 44.2 min 
(1S, 3R, 3aS, 5aR)-3i and 57.8 min (1R, 3S, 3aR, 5aS)-3i. 
1
H-NMR (300 MHz, CDCl3): δ 7.43-7.33 (m, 6H), 6.47-6.34 (m, 2H), 4.74 (d, J = 7.3 
Hz, 1H), 4.13 (s, 1H), 4.00-3.90 (m, 1H), 3.72 (s, 3H), 3.57-3.47 (m, 1H), 3.47-3.38 (m, 
1H), 1.71 (bs, 1H). 
13
C-NMR (75 MHz, CDCl3): δ 204.4, 170.6, 150.3, 142.5, 141.8, 128.8, 127.3, 110.6, 
107.8, 71.5, 59.1, 53.2, 52.3, 48.4, 29.8. 
HRMS (ESI+): calcd for C18H18NO4, 312.1236; found, 312.1232 ([M+H], 100). 
 
(1S, 3R, 3aS, 5aR)-Methyl-5a-phenyl-3-(thiophen-2-yl)-4(oxo)heptahydrocyclo-
buta[c]pyrrole-1-carboxylate (endo-3j). 
Following the typical procedure, the reaction of 3-
phenylcyclobutenone 2a (14.4mg, 0.1 mmol) and 1j (36.6 mg, 0.2 
mmol) afforded, after purification by silica gel flash 
chromatography (cyclohexane/EtOAc 6:1), the cycloadduct endo-3j (24.5 mg, 75%, 
yellow oil). 
[α]D
20 : +51.0 (c=0.22, CHCl3), 80% ee. 
SFC: The enantiomeric excess was determined by SFC using a Chiralpak-IC column 
[CO2/MeOH from 95:5 to 60:40 in 8 min, 2.0 mL/min (λ = 230.4 nm)]: tR= 4.578 min 
(1S, 3R, 3aS, 5aR)-3j and 6.07 min (1R, 3S, 3aR, 5aS)-3j. 
1
H-NMR (300 MHz, CDCl3): δ 7.33-7.27 (m, 2H), 7.25-7.17 (m, 2H), 7.16-7.12 (m, 
2H), 7.02 (d, J = 3.6 Hz, 1H), 6.89 (dd, J = 5.0, 3.6 Hz, 1H), 4.85 (d, J = 7.2 Hz, 1H), 
4.06 (s, 1H), 3.82 (ddd, J = 7.1, 3.7, 1.6 Hz, 1H), 3.60 (s, 3H), 3.41 (dd, J = 18.6, 1.6 
Hz, 1H), 3.32 (dd, J = 18.6, 3.7 Hz, 1H), 2.82 (bs, 1H). 
13
C-NMR (75 MHz, CDCl3): δ 204.8, 170.5, 142.0, 140.2, 128.9, 128.8, 127.4, 127.3, 
127.0, 126.0, 125.3, 125.0, 71.4, 61.1, 53.6, 52.2, 48.2, 29.9. 
HRMS (ESI+): calcd for C18H18NO3S, 328.1007; found, 328.0991 ([M+H], 100). 
 
(1S, 3S, 3aS, 5aR)-Methyl-3-cyclohexyl-5a-phenyl-4-(oxo)heptahydrocyclo-
buta[c]pyrrole-1-carboxylate (endo-3k). 
Following the typical procedure, the reaction of 3-
phenylcyclobutenone 2a (14.4mg, 0.1 mmol) and 1k (36.6 mg, 
0.2 mmol) afforded, after purification by silica gel flash 
chromatography (cyclohexane/EtOAc 6:1), the cycloadduct endo-3k (20.9 mg, 64%, 
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colorless oil). 
[α]D
20 : +60.1 (c=0.22, CHCl3), 72% ee. 
HPLC: The enantiomeric excess was determined by HPLC using a Daicel Chiralpak IA 
column, n-hexane/isopropanol 95:5, flow rate 0.7 mL/min (λ = 210.8 nm): tR= 19.7 min 
(1R, 3R, 3aR, 5aS)-3k and 21.8 min (1S, 3S, 3aS, 5aR)-3k. 
1
H-NMR (300 MHz, CDCl3): δ 7.42-7.35 (m, 2H), 7.32-7.27 (m, 3H), 4.00 (s, 1H), 
3.81 (ddd, J = 7.3, 3.3, 1.4 Hz, 1H), 3.68 (s, 3H), 3.42-3.34 (m, 1H), 3.30 (dd, J = 18.6, 
1.4 Hz, 1H), 3.20 (dd, J = 9.9, 7.1 Hz, 1H), 2.33 (bs, 1H), 2.07-1.93 (m, 2H), 1.77-1.63 
(m, 3H), 1.39-1.00 (m, 6H). 
13
C-NMR (75 MHz, CDCl3): δ 207.0, 171.2, 142.7, 128.7, 127.2, 127.1, 75.2, 71.9, 
68.2, 52.9, 52.1, 48.0, 39.8, 31.6, 30.8, 26.4, 25.8, 25.7. 
HRMS (ESI+): calcd for C20H26NO3, 328.1913; found, 328.1907 ([M+H], 100). 
 
(1S, 3R, 3aS, 5aR)-Methyl-5a-phenyl-3-(2-bromophenyl)-2-N-(benzyl)-4-(oxo)-
heptahydro-cyclobuta[c]pyrrole-1-carboxylate (N-benzyl 
derivative of endo-3g). 
To a solution of endo-3g (116.1 mg, 0.36 mmol) in THF (15.0 
mL) at room temperature, was added successively K2CO3 (80 mg, 
0.58 mmol) and benzyl bromide (56 µL, 0.47 mmol). The mixture 
was stirred at 40 ºC for 12 h and then was cooled to room temperature. After that, water 
was added (10.0 mL) and the aqueous phase was extracted with CH2Cl2 (3 x 8 mL). The 
resulting organic phase was washed with brine (2 x 8 mL), dried over Na2SO4 and 
concentrated under reduced pressure. The residue was purified by silica gel flash 
chromatography (cyclohexane-EtOAc 3:1), to afford the N-benzyl derivative (142.8 mg, 
95%, white solid). 
M.p.: 158-160 °C. 
1
H-NMR (300 MHz, CDCl3): δ 7.71 (dd, J = 7.8, 1.5 Hz, 1H), 7.66-7.60 (m, 1H), 7.46-
7.33 (m, 3H), 7.32-7.25 (m, 4H), 7.24-7.15 (m, 3H), 6.98 (dd, J = 7.0, 2.6 Hz, 1H), 4.45 
(d, J = 7.7 Hz, 1H), 4.05-3.97 (m, 2H), 3.94 (d, J = 14.4 Hz, 1H), 3.70 (d, J = 14.4 Hz, 
1H), 3.60 (s, 3H), 3.59 (s, 1H), 3.26 (dd, J = 18.8, 5.3 Hz, 1H). 
13
C-NMR (75 MHz, CDCl3): δ 205.0, 170.9, 142.0, 134.8, 133.2, 133.0, 130.5, 130.1, 
129.6, 128.8, 128.4, 127.8, 127.7, 127.3, 127.1, 124.1, 74.4, 71.8, 67.2, 53.9, 53.8, 51.9, 
46.7. 
HRMS (ESI+): calcd for C27H25BrNO3, 490.1018; found, 490.1442 ([M+H], 100). 
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(1S, 3R, 3aS, 5aR)-Methyl-3-phenyl-5a-(4-methoxyphenyl)-4-
(oxo)heptahydrocyclo-buta[c]pyrrole-1-carboxylate (endo-3l). 
Following the typical procedure, the reaction of 3-(4-
methoxyphenyl)cyclobutenone 2b (17.4 mg, 0.1 mmol) and 1a 
(35.4 mg, 0.2 mmol) afforded, after purification by silica gel 
flash chromatography (cyclohexane/EtOAc 6:1), the cycloadduct endo-3l (28.1 mg, 
80%, white solid). 
M.p.: 134-136 °C. 
[α]D
20 : +22.7 (c=0.22, CHCl3), 90% ee. 
SFC: The enantiomeric excess was determined by SFC using a Chiralpak-IC column 
[CO2/MeOH from 95:5 to 60:40 in 8 min, 2.0 mL/min (λ = 230.4 nm)]: tR= 5.1 min (1S, 
3R, 3aS, 5aR)-3l and 6.085 min (1R, 3S, 3aR, 5aS)-3l. 
1
H-NMR (300 MHz, CDCl3): δ 7.45-7.29 (m, 7H), 6.97-6.92 (m, 2H), 4.71 (d, J = 7.3 
Hz, 1H), 4.17 (s, 1H), 3.90-3.86 (m, 1H), 3.84 (s, 3H), 3.74 (s, 3H), 3.50 (dd, J = 18.4, 
2.3 Hz, 1H), 3.38 (dd, J = 18.4, 4.2 Hz, 1H). 
13
C-NMR (75 MHz, CDCl3): δ 205.4, 170.9, 158.6, 137.0, 134.1, 128.5, 128.4, 128.0, 
127.0, 114.0, 71.3, 64.8, 55.3, 53.6, 53.4, 52.0, 47.0. 
HRMS (ESI+): calcd for C21H21NO4, 352.1549; found, 352.1538 ([M+H], 100). 
 
(1S, 3R, 3aS, 5aR)-Methyl-3-phenyl-5a-(4-fluorophenyl)-4-(oxo)heptahydrocyclo-
buta[c]pyrrole-1-carboxylate (endo-3m). 
Following the typical procedure, the reaction of 3-(4-
fluorophenyl)cyclobutenone 2c (16.2 mg, 0.1 mmol) and 1a (35.4 
mg, 0.2 mmol) afforded, after purification by silica gel flash 
chromatography (cyclohexane/EtOAc 6:1), the cycloadduct endo-3m (24.4 mg, 72%, 
yellow solid). 
M.p.: 150-152 °C. 
[α]D
20 : +12.6 (c=0.22, CHCl3), 90% ee. 
SFC: The enantiomeric excess was determined by SFC using a Chiralpak-IC column 
[CO2/MeOH from 95:5 to 60:40 in 8 min, 2.0 mL/min (λ = 210.4 nm)]: tR= 3.989 min 
(1S, 3R, 3aS, 5aR)-3m and 4.917 min (1R, 3S, 3aR, 5aS)-3m. 
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1
H-NMR (300 MHz, CDCl3): δ 7.43-7.31 (m, 7H), 7.10 (t, J = 8.6 Hz, 2H), 4.71 (d, J = 
7.3 Hz, 1H), 4.16 (s, 1H), 3.87 (ddd, J = 7.3, 4.3, 2.5 Hz, 1H), 3.74 (s, 3H), 3.53 (dd, J = 
18.4, 2.5 Hz, 1H), 3.38 (dd, J = 18.4, 4.3 Hz, 1H). 
13
C-NMR (75 MHz, CDCl3): δ 205.0, 170.8, 162.0 (d, J = 246.6 Hz), 138.1 (d, J = 3.3 
Hz), 137.0, 129.2 (d, J = 8.1 Hz), 128.5, 128.2, 127.1, 115.6 (d, J = 21.5 Hz), 76.5, 71.4, 
65.0, 53.9, 52.2, 47.1. 
19
F-NMR (75 MHz, CDCl3): δ -115.4. 
HRMS (ESI+): calcd for C20H18FNO3, 340.1349; found, 340.1356 ([M+H], 100). 
 
(1S, 3R, 3aS, 5aR)-Methyl-3-phenyl-5a-(2-methylphenyl)-4-(oxo)heptahydrocyclo-
buta[c]pyrrole-1-carboxylate (endo-3n). 
Following the typical procedure, the reaction of 3-(2-
methylphenyl)cyclobutenone 2d (15.8 mg, 0.1 mmol) and 1a (35.4 
mg, 0.2 mmol) afforded, after purification by silica gel flash 
chromatography (cyclohexane/EtOAc 6:1), the cycloadduct endo-3n (23.1 mg, 69%, 
white solid). 
M.p.: 172-174 °C. 
[α]D
20 : +33.0 (c=0.22, CHCl3), 92% ee. 
SFC: The enantiomeric excess was determined by SFC using a Chiralpak-IC column 
[CO2/MeOH from 95:5 to 60:40 in 8 min, 2.0 mL/min (λ = 210.4 nm)]: tR= 4.564 min 
(1S, 3R, 3aS, 5aR)-3n and 5.654 min (1R, 3S, 3aR, 5aS)-3n. 
1
H-NMR (300 MHz, CDCl3): δ 7.37-7.13 (m, 9H), 4.77 (d, J = 7.1 Hz, 1H), 4.10 (s, 
1H), 4.06-3.98 (m, 1H), 3.63-3.54 (m, 4H), 3.37 (dd, J = 18.4, 4.5 Hz, 1H), 2.31 (s, 3H). 
13
C-NMR (75 MHz, CDCl3): δ 206.1, 171.4, 139.0, 137.0, 136.0, 132.3, 129.3, 128.5, 
128.1, 127.7, 127.1, 126.4, 75.0, 70.0, 64.4, 53.8, 52.1, 49.2, 21.4. 
HRMS (ESI+): calcd for C21H21NO3, 336.1600; found, 336.1586 ([M+H], 100). 
 
(1S, 3S, 3aS, 5aS)-Methyl-3,3a,5a-triphenyl-4-(oxo)heptahydrocyclobuta[c]-
pyrrole-1-carboxylate (endo-3o). 
Following the typical procedure, the reaction of 2,3-
diphenylcyclobutenone 2e (22.0 mg, 0.1 mmol) and 1a (35.4 mg, 0.2 
mmol) afforded, after purification by silica gel flash chromatography 
(cyclohexane/EtOAc 6:1), the cycloadduct endo-3o (22.3 mg, 64%, white solid). 
M.p.: 152-154 °C. 
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[α]D
20 : +30.3 (c=0.22, CHCl3), 84% ee. 
SFC: The enantiomeric excess was determined by SFC using a Chiralpak-IC column 
[CO2/MeOH from 95:5 to 60:40 in 8 min, 2.0 mL/min (λ = 210.4 nm)]: tR= 4.475 min 
(1S, 3S, 3aS, 5aS)-3o and 4.745 min (1R, 3R, 3aR, 5aR)-3o. 
1
H-NMR (300 MHz, Benzene-d6): δ 7.12-7.06 (m, 3H), 7.04-6.84 (m, 12H), 4.51 (s, 
1H), 4.13 (s, 1H), 3.90 (d, J = 18.9 Hz, 1H), 3.30 (s, 3H), 3.22 (d, J = 18.9 Hz, 1H). 
13
C-NMR (75 MHz, CDCl3): δ 207.8, 171.2, 139.9, 136.3, 135.8, 128.3, 128.1, 128.0 
(bs), 127.9, 127.8, 127.2, 126.9, 126.6, 86.6, 73.3, 65.7, 55.1, 52.8, 52.5. 
HRMS (ESI+): calcd for C26H23NO3, 398.1756; found, 398.1751 ([M+H], 100). 
 
(1S, 3R, 3aS, 5aR)-Methyl-3, 5a-diphenyl-2-N-(benzyloxycarbonyl)-4-(oxo)-
heptahydrocyclobuta[c]pyrrole-1-carboxylate (endo-7). 
To a solution of endo-3a (125 mg, 0.39 mmol) in THF (16.0 mL) at 
room temperature, K2CO3 (95.8 mg, 0.69 mmol) and benzyl 
chloroformate (66 µL, 0.46 mmol) were successively added. The 
reaction was stirred at room temperature for 12 hours and the mixture 
was quenched with H2O (10.0 mL). Then the aqueous phase was extracted with CH2Cl2 
(3 x 8 mL) and the resulting organic phase was washed with brine (20 mL), dried over 
MgSO4 and concentrated under reduce pressure. The residue was purified by silica gel 
flash chromatography (CH2Cl2/TBME (tert-butyl methyl ether) 80:1) to afford the 
compound endo-7 (158 mg, 89%, orange solid). 
M.p.: 168-170 °C. 
[α]D
20 : +41.7 (c=0.22, CHCl3), 90 % ee. 
SFC: The enantiomeric excess was determined by SFC using a Chiralpak-IC column 
[CO2/MeOH from 95:5 to 60:40 in 8 min, 2.0 mL/min (λ = 210.4 nm)]: tR= 4.475 min 
(1R, 3S, 3aR, 5aS)-7 and 5.682 min (1S, 3R, 3aS, 5aR)-7. 
1
H-NMR (300 MHz, CDCl3): δ 7.51 (d, J = 7.4 Hz, 2H), 7.46 – 7.27 (m, 9H), 7.21 – 
7.13 (m, 2H), 6.93-6.84 (m, 2H), 5.44 (d, J = 10.5 Hz, 1H), 4.96 (s, 2H), 4.83 (s, 1H), 
4.27 (ddd, J = 10.5, 5.2, 2.4 Hz, 1H), 3.75 (s, 3H), 3.60 (dd, J = 18.1, 2.4 Hz, 1H), 3.27 
(dd, J = 18.1, 5.2 Hz, 1H). 
13
C-NMR (75 MHz, CDCl3): δ 200.6, 170.9, 155.1, 142.6, 138.2, 135.7, 129.2, 128.7, 
128.4, 128.0, 127.8, 127.7, 127.6, 126.3, 126.2, 75.0, 72.2, 67.8, 65.6, 55.3, 52.6, 48.2. 
HRMS (ESI+): calcd for C28H26NO5, 456.1811; found, 456.1808 ([M+H], 100). 
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5-Benzyl 4-methyl (3aR, 4S, 6S, 6aS)-2-oxo-3a,6-diphenylhexahydro-5H-furo[2,3-
c]pyrrole-4,5-dicarboxylate (endo-8). 
To a solution of endo-7 (80.0 mg, 0.18 mmol) in CH2Cl2 (5.0 mL) at 
0 °C m-chloroperbenzoic acid (≤77 % purity, 151.9 mg, 0.88 mmol) 
was added. The mixture was stirred at room temperature for 24 h and 
CH2Cl2 (5.0 mL) and a solution of saturated Na2SO3 (5.0 mL) were 
added. The organic phase was sequentially washed with a saturated solution of NaHCO3 
(5 x 10 mL), H2O (2 x 10 mL) and brine (2 x 10 mL), dried over MgSO4 and 
concentrated under reduced pressure. The residue was purified by silica gel flash 
chromatography (cyclohexane-EtOAc 4:1), to afford the lactone endo-8 (59.7 mg, 72 %, 
white solid). 
M.p.: 178-180 °C. 
[α]D
20 : + 22.4 (c=0.22, CHCl3), 90 % ee. 
SFC: The enantiomeric excess was determined by SFC using a Chiralpak-ID column 
[CO2/MeOH from 95:5 to 60:40 in 8 min, 2.0 mL/min (λ = 210.4 nm)]: tR= 5.390 min 
(3aS, 4R, 6R, 6aR)-8 and 5.615 min (3aR, 4S, 6S, 6aS)-8. 
1
H-NMR (300 MHz, CDCl3): δ 7.65 –7.57 (m, 2H), 7.49 – 7.29 (m, 10H), 7.25-7.18 
(m, 3H), 5.46 (d, J = 5.9 Hz, 1H), 5.26 (d, J = 5.9 Hz, 1H), 5.01 (d, J = 10.4 Hz, 2H), 
4.97 (s, 1H), 3.86 (s, 3H), 3.18 (d, J = 18.0 Hz, 1H), 2.90 (d, J = 18.0 Hz, 1H). 
13
C-NMR (75 MHz, CDCl3): δ 172.5 170.5, 141.0, 135.7, 135.6, 129.8, 128.5, 128.4, 
128.3, 128.1, 128.0, 127.8, 127.5, 125.3, 88.1, 70.0, 67.9, 66.0, 56.3, 53.0, 39.1. 
HRMS (ESI+): calcd for C28H26NO6, 472.1760; found, 472.1774 ([M+H], 100). 
IR (KBr, cm-1): 1708, 1755, 1794. 
 
(1S, 3R, 3aS, 4S, 5aR)-4-hydroxy-1-hydroxymethyl-3, 5a-diphenyl-2-N-
(benzyloxycarbonyl)-heptahydrocyclobuta[c]pyrrole (endo-9). 
To a solution of endo-7 (134.4 mg, 0.295 mmol) in THF (1.5 mL) a 1 
M solution of lithium aluminum hydride in THF (0.885 mL, 0.885 
mmol) was added dropwise at -78 °C. The mixture was stirred at -78 
°C for 4 h and then warmed to room temperature and stirred for 12 
hours until completion. Ethyl acetate (3.5 mL) was added, the mixture was stirred for 
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one hour and a saturated solution of aqueous ammonium chloride (5 mL) was added. 
The organic phase was separated, washed with water (10 mL) and brine (10 mL), dried 
with MgSO4, filtered and evaporated at reduced pressure. After purification by flash 
chromatography (cyclohexane/EtOAc 3:1) diol endo-9 was obtained as white solid 
(112.7 mg, 89%). 
M.p.: 172-174 °C. 
[α]D
20 : + 36.5 (c=0.22, CHCl3), 90 % ee. 
SFC: The enantiomeric excess was determined by SFC using a Chiralpak-IC column 
[CO2/MeOH from 95:5 to 60:40 in 8 min, 2.0 mL/min (λ = 210.4 nm)]: tR= 6.484 min 
(1S, 3R, 3aS, 4S, 5aR)-9 and 7.726 min (1R, 3S, 3aR, 4R, 5aS)-9. 
1
H-NMR (300 MHz, Benzene-d6): δ 7.25 (d, J = 7.4 Hz, 2H), 7.13-7.04 (m, 5H), 7.02-
6.92 (m, 6H), 6.73-6.66 (m, 2H), 5.28 (d, J = 10.4 Hz, 1H), 4.93 (d, J = 12.6 Hz, 1H), 
4.82 (d, J = 12.6 Hz, 1H), 4.24 (dd, J = 11.7, 6.3 Hz, 1H), 4.13 (dd, J = 11.7, 3.0 Hz, 
1H), 4.08 (dd, J = 6.3, 3.0 Hz, 1H), 3.80 (q, J = 7.8 Hz, 1H), 3.08 (ddd, J = 10.4, 6.8, 
3.9 Hz, 1H), 2.80 (d, J = 8.7 Hz, 1H), 2.41 (ddd, J = 12.1, 8.0, 3.9 Hz, 1H), 2.29 (dd, J 
= 12.1, 8.0 Hz, 1H). 
13
C-NMR (75 MHz, CDCl3): δ 157.9, 143.7, 140.2, 135.7, 129.3, 129.0, 128.4, 128.0, 
127.9, 127.5, 127.1, 126.3, 126.2, 73.6, 68.0, 65.3, 65.2, 63.9, 55.5, 50.4, 37.2. 
HRMS (ESI+): calcd for C27H25NO4, 430.2018 and 452.1838; found, 430.2012 
([M+H], 17), 452.1812 ([M+Na], 100). 
 
(1S, 3R, 3aS, 4S, 5aR)-Methyl-3, 5a-diphenyl-2-N-(benzyloxycarbonyl)-4-hydroxy-
heptahydrocyclobuta[c]pyrrole-1-carboxylate (endo-10). 
To a solution of endo-7 (150.0 mg, 0.329 mmol) in MeOH (5.0 mL) 
at room temperature NaBH4 (18.7 mg, 0.49 mmol) was added and the 
mixture was stirred for 2 h. Then a saturated solution of NH4Cl (5.0 
mL) was added and the resulting aqueous phase was extracted with 
CH2Cl2 (3 x 5 mL). The organic phase was washed successively with a saturated 
solution of NaHCO3 (2 x 5 mL), H2O (2 x 5mL) and brine (5.0 mL). The resulting 
organic solution was dried with MgSO4 and concentrated under reduced pressure. The 
residue was purified by silica gel flash chromatography (cyclohexane/EtOAc 1:1), to 
afford the alcohol endo-10 (98.7 mg, 65%, white solid). 
M.p.: 154-156 °C. 
[α]D
20 : + 57.8 (c=0.22, CHCl3), 90 % ee. 
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SFC: The enantiomeric excess was determined by SFC using a Chiralpak-IA column 
[CO2/MeOH from 95:5 to 60:40 in 8 min, 2.0 mL/min (λ = 210.4 nm)]: tR= 5.281 min 
(1R, 3S, 3aR, 4R, 5aS)-10 and 6.656 min (1S, 3R, 3aS, 4S, 5aR)-10. 
1
H-NMR (300 MHz, C6D6): δ 7.85 (d, J=7.5 Hz, 2H), 7.53-7.22 (m, 11H), 7.10-6.93 
(m, 2H), 5.75 (d, J = 10.3 Hz, 1H), 5.07 (s, 2H), 4.56 (s, 1H), 4.10-3.95 (m, 1H), 3.92 – 
3.82 (m, 1H), 3.79 (s, 3H), 2.87– 2.65 (m, 2H), 1.16 (d, J = 11.4 Hz, 1H). 
13
C-NMR (75 MHz, CDCl3): δ 171.1, 155.1, 143.0, 139.7, 136.0, 129.2, 128.9, 128.4, 
128.0, 127.9, 127.5, 127.3, 126.9, 126.3, 72.1, 67.6, 65.2, 64.6, 56.9, 52.3, 50.3, 39.2. 
HRMS (ESI+): calcd for C28H28NO5, 458.1967; found, 458.1922 ([M+H], 100). 
 
(1R, 3S, 6S, 8R, 9S)-Benzyl-5-oxo-1,8-diphenyl-4-oxa-7-azatricycle[4.3.0.0
3,9
]-
nonane-7-carboxylate (endo-11). 
To a solution of PPh3AuCl (3.25 mg, 0.0066 mmol) and AgOTf (1.69 
mg, 0.0066 mmol) in toluene (1.0 mL) at room temperature a suspension 
of alcohol endo-10 (30.0 mg, 0.066 mmol) in toluene (1.5 mL) was 
added. Then, the mixture was stirred at 110 °C for 30 minutes and Et3N (0.1 mL), 
AcOEt (5.0 mL) and H2O (5.0 mL) were succesively added. The aqueous phase was 
extracted with CH2Cl2 (3 x 3mL) and the resulting organic phase was washed with H2O 
(2 x 5 mL) and brine (2 x 5mL), dried over MgSO4 and concentrated under reduced 
pressure. The residue was purified by silica gel flash chromatography 
(cyclohexane/EtOAc 4:1), to afford the lactone 11 (27.8 mg, 99%, white solid). 
M.p.: 148-150 °C. 
[α]D
20 : + 48.2 (c=0.22, CHCl3), 90 % ee. 
SFC: The enantiomeric excess was determined by SFC using a Chiralpak-IC column 
[CO2/MeOH from 95:5 to 60:40 in 8 min, 2.0 mL/min (λ = 240.4 nm)]: tR= 5.315 min 
(1R, 3S, 6S, 8R, 9S)-11 and 6.424 min (1S, 3R, 6R, 8S, 9R)-11 
1
H-NMR, COSY (300 MHz, CDCl3, 1:0.63 mixture of rotamers. The asterisk * denotes 
the signal of the minor rotamer): δ 7.40-7.13 (m, 15 H), 5,63 (d, 
J=6.5 Hz, 1H, H5), 5,51* (d, J=6.3 Hz, 1H, H5), 5, 42* (d, J=1.5 
Hz, 1H, H3), 5, 30 (d, J=1.4Hz, 1H, H3), 5, 29* (d, J=12.5 Hz, 
2H, H4/H4’), 5.09 (d, J=12.5 Hz, 2H, H4/H4’), 4.72 (t, J=4.1 Hz, 
1H, H1), 4.69* (t, J= 4.2 Hz, 1 H, H1), 3.68 (m, 1H, H6), 3.61* 
(m, 1H, H6), 2.59 (dd, J= 12.0, 4.2 Hz, H2/H2’), 2.40 (dd, J=11.9, 
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4.7 Hz, 1H, H2/H2’. 
 
13
C-NMR, DEPT-135, HMQC, HMBC (75 MHz, CDCl3, 
1:0.63 mixture of rotamers. The asterisk * denotes the signal of 
the minor rotamer):3 δ 166.8 (1C, Ch), 154.3 (1C, Cf), 154.1* 
(1C, Cf), 139.3 (1C, CHar), 139.1* (1C, CHar), 137.0* (1C, CHar), 
136.2 (1C, CHar), 135.8 (1C, CHar), 135.7* (1C, CHar), 129.2 
(3C, CH, CHar), 128.7 (CHar), 128.6* (CHar), 128.5 (2C, CHar), 
128.3* (CHar), 127.9* (CHar), 127.6*, 127.5* (2C, CH, CHar), 
127.3 (2C, CH, CHar), 125.3* (CHar), 125.24* (CHar), 125.3 (2C, 
CH, CHar), 125.0* (2C, CH, CHar), 75.74* (1C, CH, Ca), 75.7 (1C, CH, Ca), 69.45 (1C, 
CH, Cd), 68.9* (1C, CH, Cd), 67.7 (1C, CH2, Ce), 67.6* (1C, CH2, Ce), 62.3* (1C, CH, 
Cg), 62.2 (1C, CH, Cg), 60.3 (1C, CH, Ci), 56.5* (1C, CH, Ci), 55.1 (1C, Cc), 54.5* (1C, 
Cc), 36.3 (1C, CH2, Cb), 36.4* (1C, CH2, Cb). 
HRMS (ESI+): calcd for C27H24NO4, 426.1705; found, 426.1532 ([M+H], 100). 
 
3. Preparation of racemic products for HPLC analysis. 
The racemic pyrrolidines were prepared according to the general procedure, but using 
(±)-Binap as ligand. The samples for HPLC analysis were dissolved in isopropyl 
alcohol for the determination of enantiomeric excess in the case of HPLC and 
dichloromethane for SFC, and used as quickly as possible to minimize the formation of 
decomposition products. 
 
 
4. Regiochemical and stereochemical assignment 
The relative and absolute configuration of endo-3g was unequivocally established by X-
ray crystal structure analysis of its N-benzyl derivative. 
 
CCDC 1828413 contains the supplementary crystallographic data. These data can be 
obtained free of charge from the Cambridge Crystallographic Data Center via 
https://www.ccdc.cam.ac.uk 
 
 
 
 
                                                
3. Some aromatic carbons could not be assigned from the collected spectroscopic data due to the 
complexity of the spectrum around 125.0-140.0 ppm. These signals are indicated as CHar. 
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Figure S1: X-Ray Structure of the N-benzyl derivative of endo-3g 
 
(1S, 3R,3aS, 5aR)
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CO2Me
Ph
Ph
Br
 
 
Table S1. Crystal data of 7 (Hydrogen atoms removed for clarity). 
 
Chemical formula C27H24BrNO3 
Formula weight 490.38 g/mol 
Temperature 200(2) K 
Wavelength 0.71073 Å 
Crystal size 0.076 x 0.191 x 0.427 mm 
Crystal habit clear colourless prismatic 
Crystal system orthorhombic 
Space group P 21 21 21 
Unit cell dimensions a = 7.3574(3) Å α = 90° 
 
b = 17.3491(9) Å β = 90° 
 
c = 18.2869(9) Å γ = 90° 
Volume 2334.22(19) Å3 
 
Z 4 
Density (calculated) 1.395 g/cm3 
S18 
 
Absorption coefficient 1.789 mm-1 
F(000) 1008 
 
Table S2. Data collection and structure refinement 
 
Diffractometer Bruker APEX-II CCD 
Theta range for data 
collection 
2.23 to 25.35° 
Index ranges 
-7<=h<=8, -20<=k<=20, -
22<=l<=2 
Reflections collected 21048 
Independent reflections 4274 [R(int) = 0.0597] 
Coverage of independent 
reflections 
100.0% 
Absorption correction multi-scan 
Max. and min. transmission 0.8760 and 0.5150 
Structure solution 
technique 
direct methods 
 
Structure solution program SHELXS-97 (Sheldrick 2008) 
 
Refinement method Full-matrix least-squares on F2 
Refinement program SHELXL-2014/7 (Sheldrick, 2014) 
Function minimized Σ w(Fo
2 - Fc
2)2 
Data / restraints / 
parameters 
4274 / 0 / 290 
Goodness-of-fit on F
2
 1.012 
Final R indices 
3399 data; 
I>2σ(I) 
R1 = 0.0361, 
wR2 = 0.0684 
 
 all data 
R1 = 0.0561, 
wR2 = 0.0746 
 
Weighting scheme w=1/[σ2(Fo
2)+(0.0313P)2+0.3686P] 
 where P=(Fo
2+2Fc
2)/3 
Absolute structure 
parameter 
-0.0(0) 
Largest diff. peak and hole 0.294 and -0.349 eÅ-3 
R.M.S. deviation from 
mean 
0.051 eÅ-3 
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5. HPLC charts. 
 
 
 
 
 
endo-3a 
 
 
Figure S2: (±)-endo-3a 
 
 
Figure S3: (+)-endo-3a; 90% ee 
 
 
 
 
 
 
 
 
endo-3b 
 
 
Figure S4: (±)-endo-3b 
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Figure S5: (+)-endo-3b; 98% ee 
 
 
 
 
  
 
 
endo-3c 
 
 
Figure S6: (±)-endo-3c 
 
 
Figure S7: (+)-endo-3c; 81% ee 
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endo-3d 
 
 
Figure S8: (±)-endo-3d 
  
 
Figure S9: (+)-endo-3d; 85% ee 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
endo-3e 
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Figure S10: (±)-endo-3e 
  
 
Figure S11: (+)-endo-3e; 85% ee 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
endo-3f 
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Figure S12: (±)-endo-3f 
  
 
 
Figure S13: (+)-endo-3f; 86% ee 
 
 
 
 
  
 
 
endo-3g 
 
 
Figure S14: (±)-endo-3g 
  
 
Figure S15: (+)-endo-3g; 92% ee 
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endo-3h 
 
 
Figure S16: (±)-endo-3h 
  
 
Figure S17: (+)-endo-3h; 97% ee 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
endo-3i 
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Figure S18: (±)-endo-3i 
 
 
 
Figure S19: (+)-endo-3i; 88% ee 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
endo-3j 
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Figure S20: (±)-endo-3j 
  
 
Figure S21: (+)-endo-3j; 80% ee 
 
 
 
 
 
 
  
endo-3k 
 
 
Figure S22: (±)-endo-3k 
  
 
Figure S23: (+)-endo-3k; 72% ee 
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endo-3l 
 
 
Figure S24: (±)-endo-3l 
 
 
Figure S25: (+)-endo-3l; 90% ee 
 
 
 
 
 
 
 
 
 
 
 
  
 
endo-3m 
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Figure S26: (±)-endo-3m 
  
 
Figure S27: (+)-endo-3m; 90% ee 
 
 
 
 
 
 
 
 endo-3n 
 
 
Figure S28: (±)-endo-3n 
 
 
Figure S29: (+)-endo-3n; 92% ee 
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endo-3o 
 
 
Figure S30: (±)-endo-3o 
  
 
Figure S31: (+)-endo-3o; 84% ee 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    endo-7 
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     endo-8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S32: (±)-endo-7 
 
Figure S33: (+)-endo-7, 90 % ee 
 
Figure S34: (±)-endo-8 
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     endo-9 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S35: (+)-endo-8, 90 % ee 
 
Figure S36: (±)-endo-9 
 
Figure S37: (+)-endo-9, 90 % ee 
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   endo-10 
 
 
Figure S38: (±)-endo-10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
      endo-11 
 
 
 
 
 
 
 
Figure S39: (+)-endo-10, 90 % ee 
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6. NMR spectra collection 
 
 
Figure S40: (±)-endo-11 
 
Figure S41: (+)-endo-11, 90 % ee 
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The existence of seven aliphatic carbons in compound endo-3b was determined by 
recording the 13C-NMR in benzene-d6.  
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Scaling up in the region between 47.0-54.5 ppm: 
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Scaling up in the region 62.0-79.0 ppm 
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19F-NMR spectrum: 
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COSY spectrum: 
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NOESY spectrum: 
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DEPT 135 spectrum: 
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COSY spectrum: 
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HMQC spectrum: 
 
 
 
 
HMBC spectrum: 
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The existence of an equilibrium between rotamers was evidenced qualitatively from the 
performance of a 2D NOESY experiment of compound 12 in CDCl3 (see below). In 
addition to the signals corresponding to the nuclear Overhauser effect (nOe, indicated in 
yellow) strong peaks of cross between protons in equivalent equilibrium of a pair of 
rotamers were detected (peaks EXSY, indicated in blue). These two types of signals 
easily differentiate between them in the spectrum since they appear in different phases 
(positive peaks NOE, in yellow, negative peaks EXSY, in blue).4 
 
 
                                                
4. For other examples of the use of this technique for the discrimination between rotamers, see: Rayyan, 
S.; Fossen, T.; Solheim Nateland, H.; Andersen, M. Phytochem. Anal., 2005, 16, 334 and references cited 
therein. 
